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The other mutation enriched in ribavirin-passaged populations, PB1 M645I, did not alter 1 4 2 sensitivity to any of the three nucleoside analogs. We found that the two previously identified 1 4 3 ribavirin resistant mutants, PB1 D27N and PB1 V43I, were just as sensitive as the wild type 1 4 4 PR8 strain to both ribavirin and 5FU. The PB1 D27N mutant appeared to be more sensitive than 1 4 5 WT PR8 to 5-azacytidine (13-fold increase, Dunnett's adjusted p-value < 0.0001). These data 1 4 6 suggest that the resistance phenotypes of PB1 D27N and PB1 V43I are dependent on strain 1 4 7 background. Of the five single mutants tested, only PB1 T123A and PA T97I exhibited reduced 1 4 8 sensitivity to our panel of nucleoside analogs. mutant, which was highly resistant to 5FU, exhibited reciprocal sign epistasis, as it had a 1 7 0 marked decrease in fitness while each single mutant was beneficial or neutral. Consistent with 1 7 1 the lower fitness of this mutant, it produced fewer genomes than the wild type ( Figure 2B ). The 1 7 2 PB1 M645I ; PA T97I double mutant had higher fitness than WT, suggesting that selection of 1 7 3 PB1 M645I in ribavirin-passaged populations reflected culture-adaptation rather than mutagen 1 7 4 resistance. Both PB1 D27N and PB1 V43I had dramatically reduced fitness compared with WT. The decreased fitness of PB1 V43I is consistent with previous data on its growth kinetics (20). As PB1 M645I, PB1 D27N, and the PB1 M645I ; PA T97I double mutant were not resistant to 1 7 7 any of the nucleoside drugs, we did not analyze them further. We measured the fitness of PB1 T123A, PA T97I, and the double mutant PB1 T123A ; PA T97I 1 8 0 in the presence of 25μM and 50μM 5FU to better quantify their mutagen sensitivity. We used 1 8 1 lower concentrations of drug in this serial passage experiment to avoid population extinction 1 8 2 9 we measured the rates of the four transition mutation classes impacted by 5FU ( Figure 4 ). The 2 0 9 increase in transition mutations in the PA T97I mutant with 5FU treatment was similar to that of 2 1 0 WT. In contrast, the PB1 T123A mutant, which has an increased baseline rate of C to U and G 2 1 1 to A mutations, selectively buffers against further drug-induced increases in these same classes. This phenotype is most pronounced for C to U mutations. While 15μM 5FU increased all 2 1 3 transition mutations approximately 5-fold in PR8, we observed almost no change in C to U 2 1 4 mutations in the PB1 T123A mutant. The PB1 T123A ; PA T97I double mutant also buffers 2 1 5 against C to U mutations induced by 5FU, albeit not as dramatically as the PB1 T123A single 2 1 6 mutant. Together, these data show that PB1 T123A has an increased rate for two transition 2 1 7 mutation types while also limiting further induction by 5FU treatment. Increases in viral mutation rates are often accompanied by decreases in the specific infectivity 2 2 1 of the population. Accordingly, a virus resistant to the mutagenic effects of a nucleoside analog 2 2 2 would be expected to exhibit a smaller decrease in specific infectivity upon drug treatment. We the specific infectivity of all three mutants, consistent with the drug's mutagenic effects. In all 2 2 6 cases, the magnitude of the effect was similar to that of treated WT viruses. These data indicate 2 2 7 that the observed decrease in 5FU-induced C to U mutations in PB1 T123A virus is not 2 2 8 sufficient to cause a corresponding change in specific infectivity. The observed decreases in 2 2 9 specific infectivity in 5FU are more likely due to the more common A to G and U to C mutation 2 3 0 classes. Therefore, the limited fidelity phenotype of PB1 T123 is unlikely to contribute 2 3 1 significantly to the virus' mutagen resistance. Given that the resistance phenotype of our three polymerase variants was not due to altered 2 3 5 fidelity, we evaluated their ability to resist 5FU-mediated inhibition of genome synthesis. We 2 3 6 assessed the kinetics of genome replication in the presence and absence of 100μM 5FU by 2 3 7 measuring the number of genomes in the supernatants of cells infected with each viral mutant. Treatment with 5FU caused a 10-to 100-fold decrease in genome copies generated by WT 2 3 9 relative to controls ( Figure 6 ). The PA T97I mutant exhibited a similar decrease in genome 2 4 0 output in drug. In contrast, we observed smaller decreases in genome production in drug for 2 4 1 both PB1 T123A and PB1 T123A ; PA T97I, especially at later time points. At 24 hours post 2 4 2 infection, there was no significant difference on the number of genomes for PB1 T123A. The 2 4 3 PB1 T123A ; PA T97I double mutant maintained its generally lower level of genome production 2 4 4 across multiple time points, consistent with epistatic interactions between these mutations and 2 4 5 their impact on 5FU resistance. Mutagen resistant variants have been a valuable tool for probing the determinants of RNA virus 2 4 9 mutation rates and the effect of mutation rate on viral population diversity (9, 10, 20, (27) (28) (29) (30) . We 2 5 0 therefore investigated the mechanisms through which influenza virus can resist the antiviral 2 5 1 effects of nucleoside analog drugs. We identified PB1 T123A and PA T97I as two 5-fluorouracil 2 5 2 resistance mutations that interact epistatically. We also found evidence for epistasis in the 2 5 3 previously identified ribavirin resistance mutants, PB1 D27N and PB1 V43I, as they remain 2 5 4 sensitive to drug in the PR8 genetic background. The three mutagen-resistant viruses reported 2 5 5 here are not high fidelity variants and the PB1 T123A variant paradoxically exhibits a higher 2 5 6 baseline mutation rate for certain mutational classes. We identified increased genome output as 2 5 7 the main mechanism of 5-fluroruracil resistance for PB1 T123A and resistance to drug-mediated 2 5 8 RdRp inhibition as the mechanism for the PB1 T123A ; PA T97I double mutant. with a monomeric RdRp, the influenza replicase complex is composed of three proteins; PB1, 2 6 2 PB2, and PA (44) (45) (46) . The PB1 protein is the RdRp, which is shaped like a right hand with the The PB1 T123 mutation is located within the fingers domain near where the RNA template epistatic interactions that mediate both replication fidelity and mutagen resistance. We identified PB1 T123A as a mutation that mediates resistance to 5FU, but not ribavirin or 5-2 7 2 azacytidine. While mutagen selection has been used to identify high fidelity variants in a number 2 7 3 of viral systems, the PB1 T123A virus actually has a marginally elevated mutation rate. This reduced fidelity is class-specific with the largest increase in C to U transitions. Despite its higher 2 7 5 mutation rate, this virus had higher replicative fitness than WT and produced more genomes in 2 7 6 the early stages of replication. We also found that while the baseline C to U mutation rate is 2 7 7 higher for this mutant, the mutagenic effect of 5FU on this mutational class is dramatically 2 7 8 reduced. This phenotype is similar to that of the ribavirin resistant FMDV mutant, 3D M296I (32, 2 7 9 50) and may reflect increased selectivity against misincorporation of 5FU. Our finding of 2 8 0 reduced mutagenesis, however, seems inconsistent with the specific infectivity decrease we 2 8 1 observe upon drug treatment. This may indicate that 5FU-mediated increases in the two most 2 8 2 common mutation classes (A to G and U to C) are the main contributor to the observed 2 8 3 decrease in specific infectivity with drug treatment. The most likely mechanism of resistance 2 8 4 appears to be through its increase in replicative fitness in the absence of drug ( Figure 2 ). is possible that the technical limitations in the amount of 5FU we could use for accurate 3 0 0 mutation rate measurements prevented us from observing a subtle phenotype. Even though PB1 T123A and PA T97I evolved in different passage cultures, we combined them 3 0 3 to make a double mutant. Serendipitously, we found that this double mutant exhibited the most 3 0 4 dramatic 5FU resistance phenotype of any of the mutants we tested. These two mutations led to concentrations of 5FU used for selection of resistant variants, this double mutant has a fitness 3 0 9 lower than wild type, even though it is highly resistant to the drug. This finding likely explains 3 1 0 why it did not arise within our experimentally evolved populations. The double mutant virus had 3 1 1 a nearly identical spectrum of transition mutation rates to the wild type virus and only slightly 3 1 2 13 mitigated the mutagenic effect of 5FU on C to U mutations. Drug resistance seems to be driven 3 1 3 primarily by maintaining high genomic output during 5FU treatment, an effect that appears to be 3 1 4 more pronounced compared to the PB1 T123A single mutant ( Figure 6 ). Treatment with 3 1 5 nucleoside analog led to almost no reduction in the number of genome segments that are 3 1 6 released from infected cells. This mechanism allows for more infectious viral particles to be 3 1 7 produced than wild type despite similar levels of mutagenesis and specific infectivity decreases. Our examination of two other mutagen-resistant variants further suggests the importance of identified as a mutation that limited ribavirin inhibition of RNA synthesis in a replicon system (41, 3 2 2 42). We find that this mutant is not resistant to ribavirin or other mutagenic nucleoside analogs 3 2 3 in a replication competent PR8 virus. Additionally, we found that the mutagen resistance and 3 2 4 fidelity phenotype of PB1 V43I is strain dependent. This mutation, which mediates ribavirin 3 2 5 resistance in the A/Wuhan/359/95 H3N2 and A/Vietnam/1203/04 H5N1 strains, is sensitive to 3 2 6 drug in the PR8 genetic background (20). The PB1 V43I mutant, which has been suggested to 3 2 7 be a fidelity variant even in the PR8 background (43), shows no difference in the rate of 3 2 8 transition mutations in PR8. These findings suggest that there are likely to be epistatic 3 2 9
interactions governing polymerase activity and fidelity in influenza virus, and that the ability of 3 3 0 one virus to evolve resistance to a mutagen may not be reflective of how another strain evolves 3 3 1 in the face of the same selective pressure.
14 than the effect of these compounds on infectious titer output (> 1,000-fold) (21). The 3 3 9
identification of resistant variants that maintain genome output with little impact on specific 3 4 0 infectivity suggest that inhibition of RdRp activity is the main mechanism of action for 5FU. As 3 4 1 we did not identify mutations that mediate ribavirin or 5-azacytidine resistance, we cannot say 3 4 2 whether mutagenic or non-mutagenic mechanisms are dominant for these drugs. Finally, we show that polymerases with increased replicative capacity can counteract the 3 4 5 mutagenic effects of nucleoside drugs. This is a less recognized mechanism of mutational 3 4 6
robustness, but one that is entirely consistent with population genetic theory (37, 51). The 3 4 7 efficiency of negative selection is the product of the effective population size and the average 3 4 8 mutational fitness effect. Increased genome production will lead to larger populations, and 3 4 9 strong selection will quickly purge the large numbers of mutants with lower fitness, leaving the 3 5 0 most fit sequence to dominate the mutant spectrum. This "safety in numbers" phenomenon Arnold Monto (University of Michigan). Both cell lines were maintained in growth medium and 25 mM HEPES) at 37°C and 5% CO 2 in a humidified incubator. (MDCK-HA cells) were generated by co-transfection with a pCABSD plasmid that expresses a 3 6 5 Blasticidin S resistance gene and a pCAGGS plasmid encoding the influenza A/Puerto 3 6 6
Rico/8/1934 H1N1 HA gene (52, 53) . Cells stably expressing HA were selected in growth 3 6 7 medium containing 5μg/mL Blasticidin S and were enriched for high HA expression by staining sorting on a FACSAria II (BD Biosciences). Over the course of 5 passages, cells were sorted 3 7 1 three times to achieve a final population in which >99% of cells were positive for high level HA were cloned into the pHW2000 vector (54). Briefly, genomic RNA was harvested from the and Phusion high fidelity DNA polymerase (New England Biosciences M0530) with primers Mutant PB1 and PA segments were generated in the pHW2000 vector backbone using overlap ACCTACGAC for A to G mutation rate assessment, ACCCACGGC for C to U mutation rate 4 2 1 assessment, ACCTGCGGC for G to A mutation rate assessment, and ATATACGGC for U to C 4 2 2 mutation rate assessment and mutant sequence' is its reverse complement. that had been seeded with 6.5 x 10 4 MDCK cells the previous day. After three hours of drug harvested by adding 0.5% glycerol, centrifuging for 5 minutes at 3,000 x g, and freezing at - at an MOI of 0.01. After 24 hours, supernatants were harvested and passaged 3 more times on 4 5 6 MDCK cells at an MOI of 0.01. All competitions were performed with three biological replicates. SuperScript III (Invitrogen 18080) was used to synthesize cDNA using random hexamers. Quantitative PCR was performed on a 7500 Fast Real Time PCR system (Applied Biosystems). Quencher 1 with an annealing temperature of 55°C for M segment copy number measurement. staining (59, 60). If the number of green cells in a culture was greater than 0.8 (N f /N i ) it was 5 1 0 removed from the calculation because it likely contained a pre-existing fluorescent revertant in 5 1 1 the inoculum. Cultures with this many green cells were extremely rare due to the use of a small supernatants were harvested and titered by TCID 50 . The decrease in the log of the infectious 6 9 7
titer for drug-treated samples relative to untreated samples for each virus is shown. Three were performed for each mutant against a WT PR8 virus containing a neutral genetic barcode. The statistical significance of the fitness values for each mutant relative to WT PR8 was Measurements within the ideal P 0 range of 0.1 -0.7 for the null class method are shown as filled to A, and U to C, were measured in the presence of 15μM 5-fluorouracil for the indicated viruses. For each virus and mutational class, the statistical significance of the difference in mutation 7 3 3 rates in the presence and absence of 5-fluorouracil was determined using t-tests and the Holm- Sidak correction for multiple comparisons. * = p-value < 0.05, ns = not significant. Figure 1 . Sensitivity of influenza polymerase mutants to nucleoside analogs. MDCK cells were pretreated with media containing 0µM drug, 100µM 5-fluorouracil, 20µM ribavirin, or 20µM 5azacytidine for 3 hours and then infected with virus at an MOI of 0.1. After 24 hours, cell free supernatants were harvested and titered by TCID50. The decrease in the log of the infectious titer for drug-treated samples relative to untreated samples for each virus is shown. Three replicate samples were harvested for each virus at each drug concentration and are shown along with the mean. The statistical significance of the decrease in the base 10 logarithmic titer of each mutant relative to WT PR8 was determined by one-way ANOVA with a Dunnett's multiple comparison test. * = p-value < 0.05, ** = p-value < 0.001. Figure 2 . Replicative fitness of influenza polymerase mutants. (A) Direct competition assays were performed for each mutant against a WT PR8 virus containing a neutral genetic barcode. For each competition, a 1:1 starting mixture of each virus (by infectious titer) was passaged four times on MDCK cells at an MOI of 0.01. The relative changes in the amounts of the two competing viruses were determined by quantitative RT-PCR. Relative fitness was calculated as described in Methods. Data are shown for three individual competitions along with the mean. The statistical significance of the fitness values for each mutant relative to WT PR8 was determined by one-way ANOVA with a Dunnett's multiple comparison test. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001. (B) MDCK cells were infected at an MOI of 0.1 and quantitative RT-PCR was used to measure the genome copy number. The data were analyzed using a two-way ANOVA and mutant viruses were compared with the WT using Sidak's multiple comparison test. (C) Competition assays were performed as above for the PB1 T123A, PA T97I, and the PB1 T123A, PA T97I mutant in the presence of 5fluorouracil. For each virus, a one-way ANOVA with a Dunnett's multiple comparison test was used to compare the relative fitness of drug treated virus to non-treated virus. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001 Figure 4 . Effect of 5-fluoruracil on viral mutation rate. Mutation rates were measured as in Figure 3 using a 12-class fluctuation test. The rates of four mutation classes; A to G, C to U, G to A, and U to C, were measured in the presence of 15µM 5-fluorouracil for the indicated viruses. For each virus and mutational class, the statistical significance of the difference in mutation rates in the presence and absence of 5-fluorouracil was determined using ttests and the Holm-Sidak correction for multiple comparisons. * = p-value < 0.01, ns = not significant, p <0.05. Decrease Log Spec Infectivity Figure 5 . The effect of 5-fluoruracil on the specific infectivity. MDCK cells were treated with or without 100µM 5-fluorouracil and infected with influenza at an MOI of 0.1 for 24 hours. For each sample, the infectious titer was measured by TCID50, and the genome copy number was measured by quantitative RT-PCR. The specific infectivity was calculated as the titer divided by the genome copy number. The decreases in the log10 of the specific infectivity for 100µM 5-fluorouracil treated samples relative to non-treated samples are shown for replicate measurements from two or three individual experiments. There were no statistically significant differences when the data were analyzed using a one-way ANOVA. MDCK cells were infected with wild type, PB1 T123A, PA T97I, or PB1 T123A ; PA T97I viruses at an MOI of 0.1 in either 0µM (solid lines) or 100µM 5-fluorouracil (dashed lines). Supernatants were collected at four hour intervals. The number of M genome segment copies per mL was determined by quantitative RT-PCR. Data are mean ± standard deviation for 3 replicates (Log10 scale). Genome production over time was compared in the presence and absence of drug for each virus using a two-way ANOVA with a Sidak multiple comparison test. * = p-value < 0.05, ** = p-value < 0.01, *** = pvalue < 0.001, **** = p-value < 0.0001.
